The mid-level brands profiled in this study all fall short of reaching the $1 billion benchmark set by blockbuster drugs. However, global brand teams in charge of these drugs often reach their peak annual sales by investing far less money than their blockbuster counterparts. In many cases, mid-level, or sub-blockbuster drugs, are more profitable than blockbusters.
Some mid-level brands face a Catch-22 scenario - they never reach blockbuster status, therefore they do not receive blockbuster-level commercialization investments; on the other hand, the fact that they receive lower investments could be the reason they never reach blockbuster sales.
Therapeutic Areas Antibiotics Autoimmune Diseases Cardiovascular Dermatology Gastrointestinal Inflammatory Nephrology
Table of Contents :
GLOBAL RESOURCE ALLOCATION
Figure 1.1 Mid-Level Brand Expenditures and Sales Table 1.1: Mid-Level Brand Table Figure 1.2: Mirroring Niche Allocations Early and Blockbuster Allocations Late Figure 1.3: Mid-Level Brands' Staffing Mirrors Niche Brands' Staffing Throughout Early Development
EUROPEAN MARKETING Figure 2.1: European Marketing Mix Table 2.1: European Brand Table Figure 2.2: European Total Spending Figure 2.3: European Total Staffing Figure 2.4: European Brand Activities Spending Figure 2.5: European Brand Activities Staffing
Table 3.1: US Brand Table Figure 3.1: US Marketing Mix Figure 3.2: US Total Spending Figure 3.3: US Total Staffing Figure 3.4: US Brand Activities Spending Figure 3.5: US Brand Activities Staffing